Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DS-1205c plus gefitinib in EGFR-mutant NSCLC (Japan)
jRCT2080223968Phase 1Completed
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Jul 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of DS-1205 in non-small cell lung cancer (NSCLC), sponsored by Daiichi Sankyo Co., Ltd. Primary endpoints: Safety and tolerability of DS-1205c plus gefitinib and Determination of recommended dose (RDE) of DS-1205c in combination with gefitinib. Started Jul 2018; status: completed.
02
Drugs
DS-1205
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCT2080223968.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223968.